Fluidigm Company Review & Valuation
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe.
It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents.
The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays.
Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC.
It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies.
The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001.
Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.